Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06954090 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study

Study acronym: SIGNAL
StatusEnrolling by Invitation
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Enrolling by Invitationv2 Show 4 more changesShow less
    • Primary completion date: May 31, 2026 to Nov 30, 2026
    • Start date changed from estimate of Jun 1, 2025 to Nov 20, 2025
    • Study completion date: Dec 31, 2026 to May 31, 2027
    • Site contact updated
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Title: Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes. Aim: To explore the feasibility of using urinary proteomic risk scores in clinical practice to identify patients at risk of developing end organ damage and identify which patients should receive additional renocardiovascular protective treatment.
Trial Details
NCT Number NCT06954090
Lead Sponsor Steno Diabetes Center Copenhagen
Collaborators: Mosaiques Diagnostics GmbH
Conditions
(from sponsor)		 Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria
Related terms Albuminuria
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov